This product includes the webinar and SAM credit.


Following a brief overview on the difficulties encountered in the definition of the epidemiology, classification, diagnosis, prognosis, and therapy of peripheral T/NK-cell lymphomas, nodal peripheral T-cell lymphomas (PTCLs) will be discussed in detail. These neoplasms account for more than 60% of tumours stemming from peripheral T-lymphocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, they correspond to 4 entities: PTCL, not otherwise specified (NOS), PTCLs related to follicular helper T-lymphocytes (FTH), ALK+ anaplastic large cell lymphoma (ALCL), and ALK- ALCL. Tumour related to TFH cells represent a new category, including angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma and neoplasms lacking the morphologic characteristics of the previous two subtypes but also stemming from TFH-elements. The latter group was in the past included among PTCLs/NOS. ALK- ALCL was promoted from provisional to accepted entity because of emerging molecular evidences. In addition, the new provisional category of breast implant-associated ALCL was included. Most of the changes introduced in the Revised WHO Classification by comparison with the 2008 fourth edition are due to the extensive application of molecular techniques, including gene expression profiling and next generation sequencing. All the changes will be highlighted and discussed.

A collaborative educational event presented by Association for Molecular Pathology (AMP) and Society for Hematopathology (SH).

Speaker: Stefano A. Pileri, MD

Host: Jennifer Dunlap, MD

Duration: 1 hr

Level of Instruction: Intermediate

Last day to purchase course and claim credit: January 18, 2021

Maximum SAM credit available: 1.0

How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for 1.0 SAM credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:


Note: Join the AMP Family to purchase this content for a deep discount!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


Course Information
Course Date:
January 18, 2018
Course Objectives
  • Discuss the complexity of the approach to peripheral T-cell lymphomas.
  • Explain the four categories of nodal peripheral T-cell lymphomas.
  • Identify potential targets for innovative therapies.
WHO 2016 Updates: Nodal Peripheral T-cell Lymphomas
Speaker Information
Stephano A. Pileri MD  [ view bio ]
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
Pileri Presentation (+SAM)
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $215.00